Bruker signed a codevelopment and comarketing agreement with PreOmics for sample prep, and a partnership with Genedata for proteomics software.
The randomized data continue to distinguish Genomic Health's test for node-negative women, while new questions come to the fore node-positive disease and other areas of clinical care.
The company drew $49 from the credit facility to repay an earlier outstanding loan and expects to draw another $27 million to, in part, pay for its acquisition of GenePOC.
PerkinElmer disclosed earlier this month in its Form 10Q filed with the US Securities and Exchange Commission that it paid $219.8 million for its acquisition of Cisbio Bioassays
Evercore analysts set a price target of $30.50 for the company and said they see opportunities in DNA synthesis, NGS tools, pharmaceuticals, and DNA data storage.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
Bruker announced several new mass spectrometry products and workflows to be launched at the American Society for Mass Spectrometry Conference, held June 2-6 in Atlanta.
First, the company introduced the TimsTOF FleX mass spectrometer, which includes a software-switchable MALDI source adapted to the ESI TimsTOF Pro platform. This new combined ESI/MALDI capability enables spatially resolved omics, which the company calls SpatialOMx, on a single instrument. TimsTOF FleX comes with Bruker's prorietary 10-kHz SmartBeam 3D laser with true pixel fidelity for rapid, label-free MALDI imaging at high spatial resolution while preserving the 4D proteomics and phenomics sensitivity of the TimsTOF Pro in ESI mode. The approach enables researchers to gain insights into spatial molecular distributions in tissues from MALDI imaging, and to guide 4D omics molecular expression studies, for example on proteins, low-level cancer antigen peptides, lipids, glycans, metabolites, or xenobiotics, which cannot be observed by traditional staining or labelling techniques, the company said.
Bruker also launched IntelliSlides specifically designed to automate TimsTOF FleX workflows. The IntelliSlides come pre-inscribed with software-readable 'teach marks' on the conductive surface to indicate where to place the tissue sample, a bar code and tracking number. The company also released SCiLS Lab 2020 MALDI imaging software, now integrated with MetaboScape5.0 to provide automated annotations of lipids and metabolites in tissue molecular images in SpatialOMx.
The firm plans to use proceeds to fund commercial activities related to its ClonoSeq assay, as well as research into drug discovery and its project to map TCR antigens.
The team evaluated various technologies in an attempt to develop a framework to compare future methods against and to serve as a guide for researchers.
The project, established by the National Cancer Center of Japan, screens target genes in lung cancer to advance the development of new drugs and diagnostics.
Sema4 has launched several genomic testing services and digital tools as part of its Centrellis Health Intelligence Platform. According to the firm, the tools provide a comprehensive approach to track a patient's cancer, and are based on 250x tumor coverage and 100x normal coverage across all genes.
The research use only tools include: Patient Journey, which provides an interactive timeline visualization of the patient's health journey and offers services such as diagnoses, treatments, and molecular profiles; Cohort Builder, which offers the ability to define groups of patients according to specific parameters such has stage, histology, and treatments to understand treatment patterns, identify appropriate clinical trials, and allow data-driven decisions about patient care; and VONC, which is an automated variant curation platform using a wide array of databases to support curation of genetic information at scale with clinical evidence to recommend therapy decisions.
Using 100 million reads, the services provide clinical data about a wide range of genomic variants, gene fusion and alternative splicing, tumor mutational burden, and microsatellite instability, the firm said. Researchers can perform the services using fresh frozen, paraffin-embedded, bone marrow, blood, or saliva samples.
Adaptive Biotechnologies has appointed Kevin Conroy and Michelle Griffin to its board of directors. Board member Arnold Levine has transitioned to the firm's scientific advisory board.
Conroy currently serves as CEO and chairman of Exact Sciences. He has also served as president of Exact Sciences. Prior to joining Exact Sciences, Conroy served as president and CEO of Third Wave Technologies from 2005 to 2008.
Griffin currently serves as a board of director member and audit committee chair for Acer Therapeutics and HTG Molecular Diagnostics. Griffin previously served on the board of directors and audit committee chair for PhaseRx from 2016 to 2018, OncoGenex Pharmaceutics from 2008 to 2011, and Sonus Pharmaceuiticals from 2004 to 2008. She has also served as executive VP of operations and chief financial officer at OncoGenex from 2011 to 2013. She also held the positions of CEO, senior VP, and chief operating officer at Trubion Pharmaceuticals from 2009 to 2010, and acted as the firm's CFO from 2006 from 2009. Griffin also served as senior VP and CFO of Dendreon from 2005 to 2006.
The Columbia Solid Tumor Panel, a custom NGS panel from Pillar Biosciences, will be used at CUMC's Laboratory of Personalized Genomic Medicine.
The deals with Covance, NeoGenomics Laboratories, and Navigate BioPharma Services aim to expand access to NanoString's PanCancer IO 360 Gene Expression Panel.
The studies, which used multi-omic approaches, are part of the integrative Human Microbiome Project (iHMP) — the second phase of the Human Microbiome Project.
Using CRISPR mouse and iPS cell models, the researchers showed that a rare maternally inherited variant is a genetic modifier of two paternally inherited variants.
Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.
The researchers' model indicates that numerous admixture events took place as pastoralism arose in sub-Saharan Africa.
Never smokers make up an increasing portion of lung cancer patients, and researchers are working to tease out their genetic and environmental risk.